The central objective of this project is to maximize the intracellular therapeutic intensity of nucleotide analogues to leukemia cells. This is desirable because greater intracellular exposure to the active triphosphates is associated with clinical response. Our previous studies, however, have demonstrated limitations to the accumulation of the active nucleoside triphosphates that cannot be circumvented by simple dose escalation. The present application proposes to extend ongoing studies which have demonstrated that both biochemical and biological modulation approaches successfully increase the concentrations of active metabolites in leukemia cells, and that this is associated with improved clinical response. Specifically, a pilot protocol has been designed to evaluate the ability of granulocyte colony-stimulating factor (G-CSF) or all-trans retinoic acid (ATRA) to serve as biological modulators of the active triphosphates of ara-C (ara-CTP) and fludarabine (F-ara- ATP) in leukemia cells. This investigation will be conducted in the context of a continuous infusion of araC, during which the action of the growth regulatory molecules on the steady-state concentrations of ara-CTP will be quantitated. A second investigation will focus on the cellular pharmacokinetics of nucleotide analogue triphosphates to determine the minimum dose of fludarabine that will maximize the accumulation of ara-CTP in blasts. This information will be utilized in the design of a phase I study to permit combining multiple daily doses of fludarabine with intermittent ara-C infusions. Correlations will be sought between clinical response to remission induction therapy and the kinetics and extent of DNA fragmentation and apoptotic morphology in leukemia blasts. Ultimately, this information will provide a comprehensive rationale for the design of clinical protocols that combine growth regulatory molecules with cytotoxic antileukemia drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA055164-07
Application #
6269498
Study Section
Project Start
1998-06-05
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Jiang, Xuejie; Mak, Po Yee; Mu, Hong et al. (2018) Disruption of Wnt/?-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in FLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24:2417-2429
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Carter, Bing Z; Mak, Po Yee; Wang, Xiangmeng et al. (2017) Focal Adhesion Kinase as a Potential Target in AML and MDS. Mol Cancer Ther 16:1133-1144
Zeng, Zhihong; Liu, Wenbin; Tsao, Twee et al. (2017) High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica 102:1537-1548
Pan, Rongqing; Ruvolo, Vivian; Mu, Hong et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer Cell 32:748-760.e6
Jacamo, Rodrigo; Davis, R Eric; Ling, Xiaoyang et al. (2017) Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget 8:83354-83369

Showing the most recent 10 out of 422 publications